Comparing psoriasis treatments and care pathways using routine data
Research type
Research Study
Full title
Psoriasis care pathway analysis (PCPA): patterns and variation in health service utilisation of people treated for psoriasis
IRAS ID
123048
Contact name
Simon de Lusignan
Contact email
Sponsor organisation
Health Dynamix Limited (Representing LEO Pharma)
Research summary
This study explores what formulations, combinations of treatment, and sequence of treatments are used to treat psoriasis; there is very little primary research in this area, with data combined from different studies, to estimate what treatments might be most cost-effective. This study is funded and sponsored by LEO Pharma, a pharmaceutical company, who manufactures Dovobet®. The research is independently carried out by the Department of Health Care Management and Policy at the University of Surrey; the study is managed by Health Dynamix, an independent company providing project management.
REC name
London - Riverside Research Ethics Committee
REC reference
13/LO/0931
Date of REC Opinion
2 Aug 2013
REC opinion
Further Information Favourable Opinion